Literature DB >> 25070581

Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.

Haiyong Wang1, Litao Xu1, Xiaoyan Zhu1, Peng Wang1, Huiying Chi2, Zhiqiang Meng1.   

Abstract

Sorafenib, an antiangiogenic agent, can promote tumor invasion and metastasis. The phosphatidylinositol 3-kinase (PI3K)/Akt/Snail-dependent pathway plays an important role in tumor invasion and metastasis. Yet, little is known concerning the role of the PI3K/Akt/Snail-dependent pathway in sorafenib‑induced invasion and metastasis of hepatic carcinoma (HCC). A human HCC orthotopic xenograft model was established, and sorafenib (30 mg/kg/day) was administered orally. Tumor growth and intrahepatic metastasis were assessed, and immunohistochemistry was applied to analyze the activation of the PI3K/Akt/Snail-dependent pathway. HCC cell lines were treated with sorafenib (1, 5 and 10 µM), and proliferation, migration and invasion were assessed. Western blotting and real-time polymerase chain reaction (RT-PCR) were used to examine the related gene expression of epithelial-mesenchymal transition (EMT) markers and the PI3K/Akt/Snail-dependent pathway. Sorafenib inhibited tumor growth and promoted intrahepatic invasion and metastasis of the orthotopic tumors grown from SMMC7721-GFP cells in vivo. Additionally, sorafenib promoted EMT and invasion and metastasis of HCC cells in vitro. Importantly, sorafenib enhanced PI3K and Akt activation and upregulation of the expression of transcription factor Snail, a critical EMT mediator. The upregulation of transcription factor Snail expression by sorafenib may be related to activation of the PI3K/AKT signaling pathway. The PI3K/Akt/Snail-dependent pathway may mediate the pro-invasive and pro-metastatic effects of sorafenib on HCC by inducing EMT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25070581     DOI: 10.3892/or.2014.3352

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma.

Authors:  Hao Zhang; Qingqing Wang; Jun Liu; Haoqiang Cao
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

2.  Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway.

Authors:  Changcan Li; Xisheng Liu; Yuan Liu; Xueni Liu; Rangrang Wang; Jianhua Liao; Shaohan Wu; Junwei Fan; Zhihai Peng; Bin Li; Zhaowen Wang
Journal:  Cell Death Dis       Date:  2018-09-27       Impact factor: 8.469

Review 3.  Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment.

Authors:  Ruyin Chen; Qiong Li; Shuaishuai Xu; Chanqi Ye; Tian Tian; Qi Jiang; Jianzhen Shan; Jian Ruan
Journal:  Cancer Cell Int       Date:  2022-02-11       Impact factor: 5.722

4.  pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Authors:  Jun Li; Lehua Shi; Xiaofeng Zhang; Bin Sun; Yefa Yang; Naijian Ge; Huiying Liu; Xia Yang; Lei Chen; Haihua Qian; Mengchao Wu; Zhengfeng Yin
Journal:  Oncotarget       Date:  2016-01-19

5.  Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.

Authors:  Junjie Xu; Hui Lin; Gonghui Li; Yin Sun; Liang Shi; Wen-Lung Ma; Jiang Chen; Xiujun Cai; Chawnshang Chang
Journal:  Int J Cancer       Date:  2016-11-09       Impact factor: 7.396

6.  MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.

Authors:  Faryal Mehwish Awan; Anam Naz; Ayesha Obaid; Aqsa Ikram; Amjad Ali; Jamil Ahmad; Abdul Khaliq Naveed; Hussnain Ahmed Janjua
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

7.  Attitude of the Saudi community towards heart donation, transplantation, and artificial hearts.

Authors:  Waleed AlHabeeb; Fakhr AlAyoubi; Adel Tash; Leenah AlAhmari; Khalid F AlHabib
Journal:  Saudi Med J       Date:  2017-07       Impact factor: 1.484

8.  Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.

Authors:  Maximilian A Ardelt; Thomas Fröhlich; Emanuele Martini; Martin Müller; Veronika Kanitz; Carina Atzberger; Petra Cantonati; Martina Meßner; Laura Posselt; Thorsten Lehr; Jan-Georg Wojtyniak; Melanie Ulrich; Georg J Arnold; Lars König; Dario Parazzoli; Stefan Zahler; Simon Rothenfußer; Doris Mayr; Alexander Gerbes; Giorgio Scita; Angelika M Vollmar; Johanna Pachmayr
Journal:  Hepatology       Date:  2018-12-22       Impact factor: 17.425

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.